Meeting
2020 ASCO Virtual Scientific Program
Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS.
Authors
Abhishek Maiti
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Abhishek Maiti , Courtney Denton Dinardo , Naveen Pemmaraju , Tapan M. Kadia , Caitlin R Rausch , Kiran Naqvi , Naval Guastad Daver , Gautam Borthakur , Maro Ohanian , Ghayas C. Issa , Yesid Alvarado , Nicholas James Short , Michael Andreeff , Elias Jabbour , Sherry A. Pierce , Farhad Ravandi , Guillermo Garcia-Manero , John Sutton Welch , Hagop M. Kantarjian , Marina Konopleva
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT03404193
Citation
J Clin Oncol 38: 2020 (suppl; abstr 7519)
DOI
10.1200/JCO.2020.38.15_suppl.7519
Abstract #
7519
Poster Bd #
292
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of venetoclax in combination with azacitidine or decitabine in an outpatient setting in patients with untreated acute myeloid leukemia.
First Author: Sudhir Manda
Poster
2021 ASCO Annual Meeting
A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.
First Author: Curtis Andrew Lachowiez
Poster
2018 ASCO Annual Meeting
Validation of the ELN-2017 risk classification in younger adult patients (pts) with AML.
First Author: Prajwal Boddu
Poster
2022 ASCO Annual Meeting
Quizartinib (QUIZ) with decitabine (DAC) and venetoclax (VEN) is active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML): A phase I/II clinical trial.
First Author: Musa Yilmaz